Microrna Signatures Predicting Responsiveness To Anti-her2 Therapy

Abstract

The invention provides miRNA signatures and methods of making and using thereof. MiRNA signatures determine the responsiveness of HER2 expressing breast tumors to anti- HER2 treatment, such as the targeted drug therapy trastuzumab.


Claims

Information currently unavailable.

Download PDF
Document Preview
Document History
  • Publication: Feb 2, 2012
  • Application: Jan 26, 2011
    WO US 2011/0022606 W
  • Priority: Jan 26, 2010
    US US 29845410 P

Download Citation


Sign in to the Lens

Feedback